Johnson and Johnson Stock Gains Momentum After Promising Early Cancer Drug Trial Results
Johnson and Johnson has reached a significant clinical milestone as the healthcare giant revealed encouraging data from its recent Phase 1b study
by 
Josh Weiner
Josh Weiner